Parabilis Medicines, Inc. has filed a registration statement for an initial public offering, indicating its intention to list on the Nasdaq Global Market under the ticker symbol "PBLS," according to the company's prospectus.
The prospectus states the company intends to offer voting common stock as part of the IPO. The filing does not provide an estimated price range for the shares. A syndicate of underwriters named in the filing includes Leerink Partners, BofA Securities, Evercore ISI, Guggenheim Securities, and LifeSci Capital.
Upon completion of the offering, Parabilis will continue to have two classes of common stock in circulation - the voting shares proposed to be sold in the offering and the pre-existing non-voting common shares. The company notes that the IPO is contingent on satisfying Nasdaq Global Market listing standards.
Parabilis describes its core technology as Helicons, which the company characterizes as stabilized helical peptides engineered to engage protein targets the company says have been previously considered undruggable. The company's lead investigational agent, zolucatetide, is designed to disrupt the interaction between beta-catenin and T-cell factor family transcription factors within the Wnt/beta-catenin signaling pathway.
According to the prospectus, zolucatetide has been administered to in excess of 150 patients spanning a range of solid tumor indications. In the filing, Parabilis reports that patients with desmoid tumors experienced tumor reductions in all treated individuals, and that among patients who completed at least two post-baseline scans the objective response rate was 74%.
The filing reiterates the biological role of the Wnt/beta-catenin pathway, noting it regulates cell proliferation and differentiation and that its hyperactivation is implicated in cancer development across multiple tumor types. The document also notes that, prior to this proposed offering, Parabilis common stock was not available on public markets.
This registration marks the company’s move to access public capital markets while advancing a clinical-stage program built around a peptide platform targeting intracellular protein interactions. The prospectus provides clinical detail and the listing plan but leaves the proposed share price range unspecified, and the offering remains subject to Nasdaq's listing requirements.